Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > European heavy weights share their wisdom on how to deal with COVID-19 and cancer
  • News

European heavy weights share their wisdom on how to deal with COVID-19 and cancer

  • 24 April 2020
  • Editorial Staff
European heavy weights share their wisdom on how to deal with COVID-19 and cancer
Total
0
Shares
0
0
0
0
0

The consortium Cancer Core Europe has collected, elaborated and shared the steps top experts have taken, while scientific evidence is still in the making

Several top cancer centres from all around Europe have just published the results of their in-depth analysis of the challenges posed by the COVID-19 pandemic, that imposes a new way of balancing the risks and benefits associated to the delivery of cancer care.

The seven institutions – the Netherlands Cancer Institute, Karolinska Institute, Institute Gustave Roussy, Cambridge Cancer Center, Istituto Nazionale dei Tumori di Milano, German Cancer Research Center and Vall d’Hebron Institute of Oncology – had already joined forces when they decided to launch in 2014 a consortium called “Cancer Core Europe” (CCE) with the goal of working together to define and share the best practices in cancer research and care. In recent weeks, they worked together on the measures that appear to be the most reliable – although they clearly are still provisional – to assure that cancer patients receive the best possible assistance and care.

Caring for patients “in a parallel universe”

“Together, the consortium represents ~60,000 patients with newly diagnosed cancer, delivers ~300,000 treatment courses and sees ~1,200,000 consultations annually. Furthermore, >1,500 clinical trials are being conducted at CCE” the international team led by Joris van de Haar wrote in a comprehensive review on cancer and COVID-19 recently published in Nature Medicine (van de Haar, J., Hoes, L.R., Coles, C.E. et al. Caring for patients with cancer in the COVID-19 era. Nat Med (2020),  available in open access). “Since these seven comprehensive cancer centers play important roles both nationally and internationally, CCE decided on 24 March 2020 to collect, translate and compare all guidelines put in place to combat cancer during the COVID-19 pandemic.

”The researchers focused on adult cancers, and collected all the measures and approaches that were adopted locally, sometimes as a general guidance for the whole hospital and sometimes as detailed guidelines specific for each cancer type, always recognising that “most measures adopted have been based on educated assumptions and expert opinions, influenced or supported by information extrapolated from other infectious diseases”.

This drastically modified the usual context, which they described as “like practicing medicine in a parallel universe”.

Watchful search for new evidence and rapid reaction times are needed

While having to face shortages in personal protective equipment, beds, personnel and other dire challenges, the seven institutions adopted a list of measures (see below), with differences that depend in part on the fact that healthcare services are organised differently in each country, and on the lack of published evidence, but also on the “sense of urgency for action” in each country over time, while the COVID-19 pandemic unfolded: “Now and in the time to come, the course of the COVID-19 pandemic will determine how and to what extent oncological care needs to be re-organized. This will probably be a dynamic and quickly evolving process, for which we hope our collective experiences so far can offer guidance to others globally” they write.

General consensus measures taken by CCE centers during the COVID-19 pandemic

Hospital wide 

  • Construct a hospital-wide crisis team responsible for coordinating measures between departments.
  • Encourage patients not to arrive early. Offer to text patients when you are ready to see them, so they can wait outside or in the car.
  • Instruct patients not to visit the hospital if they have symptoms indicative of possible COVID-19 (unless urgent attention is required).
  • Call patients the day before planned hospital admissions, to discuss the presence of any COVID-19-related symptoms.
  • Screen patients at the entrance for symptoms of COVID-19 and fever.
  • Quickly isolate patients with COVID-19 in specialized departments, with the intent of relocation to regional collaborating hospitals (if possible).
  • Reduce preclinical research activities to a bare minimum.
  • Stop patient inclusion for clinical studies or trials requiring additional actions and/or visits.
  • Consider a tumor type–specific ‘exception list’ of particularly successful studies for which inclusion continues.
  • Discuss each patient with a multidisciplinary team to consider alternative treatment modalities with the fewest visits or lowest capacity problems or that are the shortest in duration.Therapeutic adjustments (versus regular guidelines) should be discussed in a multidisciplinary team meeting.
  • Conduct multidisciplinary team consultations remotely if possible or include only one representative of each discipline to limit the number of people participating in the meetings.
  • Inform patients about a possibly increased risk associated with anticancer therapy during the COVID-19 pandemic.
  • Enable telephone or video consultations for healthcare professionals who need to self-isolate.
  • When postponing procedures or contact moments, anticipate future capacity problems.
  • Do not prescribe corticosteroids as anti-emetics (if avoidable), and limit their use in patients treated with immune-checkpoint blockade, to reduce vulnerability to COVID-19.
  • With each patient, discuss resuscitation status to anticipate future decisions about intensive care.

Outpatient clinic

  • Critically triage second opinions.
  • Do all follow up appointments by phone (except when physical examination is necessary).
  • When possible, reduce or delay the number of radiological-response evaluations.
  • Prioritize oral or subcutaneous treatments above infusion-based treatments to reduce time spent in the hospital.
  • Perform blood tests outside the hospital (e.g., at a general practice or at home), when possible.
  • Have oral medications delivered to the patient’s home, rather than being picked up at the pharmacy.

Day care

  • Consider omitting supportive treatments (e.g., no bisphosphonate infusion, except in the case of hypercalcemia).
  • When possible, organize the administration of intravenous maintenance treatments at home.
  • When administration at home is impossible, consider temporary breaks or reductions in the frequency of intravenous maintenance treatments for less-aggressive metastatic cancers on a per-patient basis.

Radiotherapy

  • Consider hypofractionated regimens for patients with limited additional benefit of regular regimens.
  • Create capacity for radiation as replacement of surgery.

Surgery

  • Consider postponement of surgeries with high morbidity and mortality during the pandemic.
  • Consider other treatment modalities with equal benefit (e.g., radiation for prostate cancer, curative chemoradiation for other tumor types, or brain irradiation for metastases).

Other recommendation

  • Consider outsourcing of interventions (e.g., follow-up endoscopies) to private clinics.
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • covid-19
Editorial Staff

Previous Article
  • Articles
  • Practice Points

Covid-19 pandemic: information and resources to support the cancer care community

  • 24 April 2020
  • Cristina Ferrario
View Post
Next Article
  • News

Gender equality in cancer research is still far away

  • 27 April 2020
  • Cristina Ferrario
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Yeva Margaryan
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Yeva Margaryan
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
1 comment
  1. Pingback: Covid-19 pandemic: information and resources to support the cancer care community - Cancerworld

Comments are closed.

search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.